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Bone marrow changes following treatment of renal anemia with eryth-
ropoietin. In 14 severely anemic patients with end-stage renal disease
and chronic hemodialysis the effect of recombinant human erythropoi-
etin (EPO) on hemopoiesis was investigated. Bone marrow biopsies
were taken before and after four and 26 months of treatment with EPO
to evaluate quantitative and qualitative changes of histomorphology.
EPO induced normalization of maturation and an increase in cell mass
of the erythropoietic line in all patients. The number of megakaryocytes
also increased significantly with EPO treatment (P < 0.01). At the time
of the third bone marrow biopsy (26 months) erythropoiesis was
normal. Megakaryopoiesis remained unchanged compared to the sec-
ond biopsy (4 months). No cytomorphologic abnormalities or other
evidence for malignant disorder could be detected in any of the patients.
Hematocrit increased from a mean of 19 to 31 percent at the second
evaluation (P < 0.001). Platelet count had risen by a mean of 30,000 at
four months (P < 0.05) and slightly decreased at 26 months. These
observations suggest great safety of long-term treatment with recombi-
nant human erythropoietin, and demonstrate efficacy in correcting
reduced and immature erythropoiesis in chronically hemodialyzed
patients. EPO also stimulates human megakaryopoiesis.
Erythropoietin (EPO) is the primary humoral regulator of red
cell production by directly stimulating proliferation and differ-
entiation of the erythroid precursor cells [1, 2]. Its clinical
effectiveness in the treatment of renal anemia has been well
established [3—6]. Since recombinant DNA techniques now
provide sufficient quantities of EPO, a broader clinical use in
anemias of other origin becomes possible [7]. Using bone
marrow cell cultures and animal models, numerous studies have
shown the stimulating effect of this hormone on erythropoiesis
[8, 9]. Observations concerning the influence of EPO on other
cell lines including the pluripotential stem cell have remained
controversial [10—121. Continuous stimulation of marrow
growth by high or ultra-high doses of EPO has raised the
question of any risk for such treated patients to develop
malignant disorders of the hematopoietic system [131. This
issue is of even more concern in renal patients because of toxic
damage of the bone marrow and the high cell turnover due to
reduced hematopoietic cell mass and/or chronic blood loss
combined with reduced red cell survival time [14, 15].
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The major purpose of our study was to investigate effects of
short- and long-term EPO treatment on bone marrow histomor-
phology, not previously reported in humans, and to elucidate
the question of whether long-term EPO treatment may lead to
any signs suggesting the induction of hematopoietic malig-
nancy. Also, we wished to examine whether cell lines other
than the erythroid lineage are effected. Therefore, histomor-
phometry was used to quantify hemopoiesis accurately.
Methods
Patients
All 25 patients with anemia because of chronic renal disease
cared for in our hemodialysis unit were evaluated for the study.
Fourteen met the entry criteria and gave informed consent to
participate in the study. These criteria included hemoglobin
values below 8 g/dl for the last four weeks prior to entering the
study, absence of aluminum overload (serum aluminum con-
centration of less than 5 pg/liter), folate or vitamin B 12 defi-
ciency, or microcytic anemia. The 14 patients (7 males, 7
females), mean age 42 years, range 21 to 78, had been on
chronic hemodialysis three times per week for a mean of 62
months, range 9 to 199 months (Table 1). Causes for end-stage
renal disease included chronic pyelonephritis in five patients,
rapidly progressive glomerulonephritis in three, and in one each
cystic kidney disease, EPH-gestosis, hemolytic uremic syn-
drome and diabetic nephropathy. Two patients were anephric.
Thirteen out of 14 patients had received blood transfusions
during the year prior to study (mean 8 transfusions, range 2 to
24). Slightly decreased serum ferritin levels with normal serum
iron concentration and normal MCH were present in two
patients.
Study protocol
Recombinant human EPO (Cilag, Schafflausen, Switzerland
and Boehringer Mannheim, Mannheim, Germany) was admin-
istered intravenously three times per week at the end of
hemodialysis at an initial dose of 80 U/kg in five and 60 U/kg in
nine patients. Two doses were given initially because of slightly
different study protocols for the two EPO products. Since the
results were not different for the two dose regimens only
combined results will be presented. The dose of EPO was
increased stepwise by 20 units per kilogram of body weight to a
maximum of 160 units per kilogram based on the response of the
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Table 1. Patient data and peripheral blood count, erythropoiesis and megakaryopoiesis at baseline, second and third bone-marrow biopsy
(BMB)
Erythropoiesis
Patient
no/age/sex
Red cells 1O5/pJ Platelets 1O/pJ myeloid:erythroid ratio MegakaryOpoiesis cells/mm2
Baseline BMB2 BMB3 Baseline BMB2 BMB3 Baseline BMB2 BMB3 Baseline BMB2 BMB3
1 21, f 2.3 4.0 TX 257 320 — 10:1 5:1 — 10 25 —
2 35,f 1.8 3.5 3.7 157 237 252 8:1 6:1 6:1 16 20 20
3 51, f 2.5 3.1 2.9 215 231 198 8:1 3:1 5:1 16 41 25
4 55,f 2.0 2.6 4.3 71 90 154 6:1 3:1 4:1 24 27 23
5 31,f 1.8 3.4 TX 172 232 — 8:1 6:1 — 21 23 —
6 45, m 2.1 3.2 4.1 175 250 226 7:1 4:1 4:1 21 21 23
7 23, m 1.5 2.3 TX 89 129 — 6:1 3:1 — 21 42 —
8 28, m 2.5 2.4 TX 174 195 — 7:1 5:1 — 28 17 —
9 27, m 2.0 3.4 rf 220 246 — 8:1 6:1 — 18 27 —
10 78,f 2.6 3.5 3.5 322 254 266 9:1 5:1 6:1 16 21 20
11 42, m 2.2 3.6 3.4 238 257 249 6:1 5:1 5:1 20 19 21
12 35,m 1,6 3.9 3.1 98 194 193 10:1 4:1 5:1 10 39 20
13 56, m 2.0 2.3 dec 171 171 — 5:1 4:1 — 16 36 —
14 62,f 2.4 3.4 3.0 164 223 116 6:1 5:1 5:1 20 24 26
Mean 42 2.1 3.2a 35b 180 210 207' 18 27 221
The myeloid:erythroid ratios were: 5:1 to 4:1 for normal; 3:1 for slightly increased; 2:1 for moderately increased; 1:1 for markedly increased;
6:1 to 7:1 for slightly decreased; 8:1 to 9:1 for moderately decreased; 10:1 or more for markedly decreased. Abbreviations are: TX, renal
transplantation; rf, refused; dcc, deceased.
a P < 0.05 compared to baselineb No change to second BMB
hematocrit. This dose was not exceeded in order to prevent
such complications as hypertension. Iron supplements were
started at serum ferritin levels below 50 sg per liter. Baseline
bone marrow biopsies (BMB) were taken from the posterior
iliac crest by means of a manual trephine [161 before EPO
treatment was commenced. Follow-up biopsies were carried
out after a mean of 16 weeks (range 9 to 29). Ten patients had
their second BMB at hematocrit values between 30 to 38
percent. In four patients the hematocrit remained below 30
percent. A third biopsy was taken in the remaining eight
patients after 112 weeks (range 85 to 113). Four patients were
withdrawn from the study because of kidney transplantation,
one patient (No. 13) died of myocardial infarction and one
patient refused further biopsy.
Laboratory analysis
Histomorphologic evaluation of the bone marrow [17] was
preferred to bone marrow aspiration and to the plasma clot
method [12] to avoid variations caused by different amounts of
blood drawn during marrow aspiration [131.
All BMB specimens were embedded in methyl-methacrylate
without decalcification. Sections cut at 3 tm were stained with
Giemsa for cytological detail, Gomori's stain for reticulin fibers
and Prussian blue for iron [181. In addition, bone structure was
examined and classified according to Delling [19]. Only sections
containing bone marrow areas of more than 30 mm2 were used
for histologic and histomorphometric measurements, which
were made with a Zeiss integration disc in the focusing eyepiece
(x 8) on a minimum of 10 microscopic fields at 400 x magnifi-
cation. Megakaryocyte numbers were calculated as average out
of these fields, with five sections examined per patient before
treatment and at the time of the second and third biopsy.
Erythropoiesis was assessed semiquantitatively by evaluat-
ing the myeloid:erythroid ratio (ME) as follows: 5:1 to 4:1 for
normal erythropoiesis, 3:1 for slight, 2:1 for modest and 1:1 for
marked increase and 6:1 to 7:1 for slight, 8:1 to 9:1 for modest
and 10:1 or more for marked decrease in erythropoiesis. All
slides were coded and assessed by three independent observ-
ers, who were thus blinded to the patients' identities and the
fact whether a biopsy was obtained in the basal state or at the
second or third evaluation.
All blood samples were drawn shortly before biopsies were
taken and 24 hours after the last hemodialysis treatment. The
complete blood count was obtained by a standard automated
counter in whole blood.
Statistical analysis
For statistical analysis the microcomputer version of the
Statistical Package for the Social Sciences was used [20]. The
paired Student's t-test was used for the comparison of baseline
and follow-up data and linear regression analysis was used to
correlate the observed changes with various parameters.
Results
Histological data
Baseline. Megakaryopoiesis and granulopoiesis were normal
at baseline examination. In comparison to normal bone marrow
two patients showed a severe and 11 patients showed a slight or
moderate decrease of erythropoiesis. A shift or erythroid pre-
cursors towards more immature stages prior to treatment could
be detected in 13 out of 14 patients (Fig. 1 A and B). One patient
(No. 13) had normal erythropoiesis. Dyserythropoietic changes
such as nuclear irregularity, multinucleation or internuclear
chromatin bridge formation were not found. Siderin was miss-
ing in one, decreased in four, normal in three and increased in
six patients. Renal osteodystrophy was present in all patients.
The degree of the bone changes was more pronounced in
patients with a long history of hemodialysis. Six patients
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Fig. 1. Representative examples (patient No. 1) with hypocellular bone marrow (Giemsa stain). A. Reduced erythropoiesis prior to EPO treatment(x50). B. Reduced number of erythrons showing a shift of erythroid precursors towards more immature stages (arrow heads) and a few
megakaryocytes (arrow) (x250). C (>50) and D (x280): Bone marrow after EPO treatment. Slightly increased, qualitatively normal erythropoiesis
(arrow heads). An increased number of megakaryocytes compared to the baseline status can be noted (arrows).
revealed renal osteodystrophy Type I, seven Type II and one
Type III.
Second bone marrow biopsy. At the time of second BMB
megakaryopoiesis was increased significantly, but did not show
any abnormalties or cytological atypias (P < 0.01, Table 1). No
changes were observed with regard to granulopoiesis and the
patients' bone status. EPO treatment had normalized matura-
tion and increased erythropoiesis in all 14 patients (Fig. 1 C and
D), including patient No. 13, whose bone marrow proved to be
normal with slight reduction in siderin at baseline examination.
Three of them even showed a slight increase above qualitatively
normal erythropoiesis (Table 1). Siderin was missing in two,
decreased in four, normal in four and still increased in four
biopsies at the second evaluation.
Third bone marrow biopsy. At the time of third BMB (mean
26 months) the number of megakaryocytes had remained un-
changed compared to the second biopsy. Granulopoiesis and
erythropoiesis showed normal values. No cytological abnor-
malities or shift to the left could be detected in any of the cell
lineages. Siderin was normal in six and remained increased in
two biopsies after 26 months.
Clinical data
Values at time of baseline examination. The 14 severely
anemic patients had a hemoglobin below 8 g!dl (Table 1).
Values at time of second bone marrow biopsy. Following
commencement of EPO treatment, 13 patients responded to
therapy. There was no need for further blood transfusions in all
14 patients. Red blood cells had increased by a mean of 1.1
million/zl and hemoglobin by a mean of 3.8 g/dl (mean 10.4
g!dl). A significant increase in platelet count by a mean of 30,000
per d was also found (P < 0.01). Hematocrit increased from a
mean of 19 to 31 percent (P < 0.001). No correlation was found
between uremic parameters, sex, age, history of hemodialysis
and the histological changes and/or changes in peripheral blood
cell count. In four patients a target hematocrit of 30 to 38
percent was not obtained despite doses of up to 160 units per
kilogram of body weight. They were biopsied for the second
time at hematocrit values below 30 percent. Patient No. 8, was
re-biopsied after he began to suffer from av-fistula infection and
continuously dropped his hematocnt. With the end of infection
and iron supplementation his blood count again improved.
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Patient No. 13 required no further transfusions, but a marked
increase in hematocrit could not be obtained. Bone marrow
biopsies showed a normal erythropoiesis with slightly de-
creased siderin levels before treatment. Even with intravenous
administration of iron and improved serum ferritin levels,
hematocrit remained low. Serum transferrin levels were within
the normal range over the entire study period. No signs of
clinically relevant hemolysis or chronic blood loss could be
detected. In patients No. 4 and No. 7 the EPO dose was not
increased above 160 units per kilogram of body weight because
of problems with hypertension.
Values at time of third bone marrow biopsy. After 26 months
of treatment the remaining eight patients had established mean
hemoglobin values of 11.4 g/dl (range 8.6 to 13.0 gIdl). Red cell
count and platelet count showed no significant changes com-
pared to the values at the second BMB.
Statistical correlations
By correlating results of peripheral blood count and histo-
morphology at baseline with those of the second biopsy, a
relationship between red cells and platelets could be observed
in our patients. The higher the degree of anemia present at
baseline, the more pronounced was the degree of thrombopenia
(P < 0.01, r = 0.70, Fig. 2A) [20]. The lower the platelet count
at baseline, the higher was their increase expressed as percent-
age of initial value (P C 0.01, r = —0.69). Correlating the
percentage of initial value in red cells with the percentage of
initial value in platelet count at the time of second biopsy, a
significant correlation was found in our patients (P C 0.01, r =
0.75, Fig. 2B). No correlation could be detected between either
platelet count and megakaryopoiesis, or between red cell count
and erythropoiesis at both baseline examination and after
commencement of EPO. There was also no correlation between
the changes in platelet count and megakaryopoiesis, as well as
the changes in red cell count and erythropoiesis.
Discussion
Numerous studies have indicated that uremic toxins, short-
ened red cell survival, inhibitors of erythropoiesis and inade-
quate EPO production contribute to the genesis of anemia in
patients with chronic renal failure [15, 21, 22]. A reduced red
cell production due to a lack of stimulation of the erythroid
marrow has been proposed as the main reason [23, 24].
In our patients EPO caused an increase in erythropoiesis and
normalization of maturation of red cells. Lack of responsive-
ness in patient No. 13 might be due to impaired iron utilization
or the need for a higher dosage [25]. No changes were observed
concerning granulopoiesis and white blood cell count after EPO
treatment. Nevertheless, the results of our study show that the
response to therapeutic doses of EPO is not restricted to the
erythroid lineage [11]. Using cell culture methods, animal
models, or measurement of human hematopoietic progenitor
cells from bone marrow aspirates or whole blood [9, 12, 13, 26],
several but not all investigators have shown a stimulating effect
of the hormone on megkaryopoiesis [27—32]. To provide an
accurate quantification we chose histomorphologic evaluation
and found a significant rise in the number of megakaryocytes in
comparison to baseline values (P C 0.01). This has not been
previously reported in humans [33—35]. As might be expected
from these findings, a slight but significant rise in platelet count
was observed at the second biopsy (P C 0.05). Eschbach et al
[25] have shown a similar increase of platelets in a large number
of predialysis patients with renal anemia, but did not study
megakaryopoiesis. Theoretically, an improvement in platelet
survival time could explain the increased platelet count. How-
ever, with an unchanged amount of uremic toxins, and consid-
ering the high turnover of these cells in patients on chronic
hemodialysis on one hand and an increased megakaryocytic cell
mass on the other hand, this possibility seems very unlikely.
Also, controversial results have been published on changes in
red cell survival time and therefore do not help to settle this
issue [36, 37]. Since it would entail the use of isotopes, platelet
survival measurements were not carried out in our patients. The
theory of a reactive thrombocytosis due to iron deficiency could
not be supported by a correlation of platelet count to ferritin
serum levels in our study [25].
Considering that all other conditions were kept stable over
the study period, in particular that hemodialysis treatment was
provided according to accepted standards (with kt/v around I as
defined by Gotch [38]), our histological results provide evidence
for a direct stimulation of the megakaryocytic cell line by EPO
[39, 40]. Alternatively, this effect could be indirect with EPO
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In conclusion, we have shown that recombinant human
erythropoietin is able to correct reduced and immature eryth-
ropoiesis in patients with renal anemia. A stimulating effect of
EPO on the megakaryocytic cell line previously found in cell
cultures can also be shown in humans using histomorphometry.
In this very small group of eight patients, continuous therapy
did not lead to the development of malignant disorders of any
hematopoietic cell line over the observed period of 26 months.
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